Russian hospitals may face with a shortage of some vital and other drugs this year, due to massive disruptions in public procurements, according to recent statements by representatives of hospitals, reports The Pharma Letter’s local correspondent.
The main reason for this will be the introduction of a new methodology for setting the maximum price for state contracts by the Russian Ministry of Health.
According to official state statistics, in the first half of 2019 the number of failed state drug purchases almost doubled compared to the same period last year.The conduct of the majority of tenders was cancelled due to the lack of applications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze